JAGX - Jaguar Health, Inc.
0.3944
-0.015 -3.905%
Share volume: 175,430
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$0.41
-0.02
-0.04%
Fundamental analysis
53%
Profitability
50%
Dept financing
50%
Liquidity
21%
Performance
64%
Performance
5 Days
-3.76%
1 Month
-0.70%
3 Months
-46.75%
6 Months
-81.22%
1 Year
-95.11%
2 Year
132.14%
Key data
Stock price
$0.39
DAY RANGE
$0.39 - $0.41
52 WEEK RANGE
$0.31 - $13.25
52 WEEK CHANGE
-$96.38
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-24-2025
NEXT EARNINGS DATE
05-13-2025
Company detail
CEO: Lisa A. Conte
Region: US
Website: jaguar.health
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: jaguar.health
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Jaguar Health, Inc. focuses on developing prescription medicines for people and animals with gastrointestinal distress. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera.
Recent news